anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For the BEEHIVE Study, UT seeks to enroll 1,500 participants living in the greater Salt Lake City area during the upcoming 2023-2024 COVID-19 season. Participants who intend to get vaccinated with the 2023-2024 updated COVID-19 vaccine (n=1200) will be randomized into the NVX vaccine group or the Pfizer mRNA vaccine group. Participants will be randomized 1:1 to receive 1 dose of the NVX vaccine versus 1 dose of the Pfizer mRNA vaccine from October to December 2023 (dates may vary slightly based on vaccine availability). Participants who decide not to receive a 2023-2024 updated COVID-19 vaccine during this period will be placed in a non-randomized comparison group (n=300).

Participants in all three study arms will complete an online enrollment survey and will self-schedule an in-person enrollment visit. During the visit, all participants will receive a supply of at-home rapid antigen tests for SARS-CoV-2 infection. Those who choose to be in the vaccinated group will also receive either the Novavax vaccine or the Pfizer mRNA vaccine at random. On the first, second, and seventh day after receiving the vaccine, participants will complete an online post-vaccination survey. Beginning after the enrollment visit for a period of 24 weeks, all participants will complete a weekly rapid at-home test and a weekly online survey that surveils for COVID-like illness (CLI)-associated SARS-CoV-2 virus infection, defined as symptoms in the past 7 days including: fever; chills; malaise; fatigue; headache; cough; shortness of breath; sore throat; runny nose or nasal congestion; nausea or vomiting; diarrhea; muscle or body aches; or change in smell or taste. Participants will upload a photo of each weekly test result to the study portal. Those who report new CLI symptoms and those who test positive on their at-home test will complete additional online surveys concerning their illness, as well as another at-home test on the first and third day after the original test. Additionally, all participants will complete a mid- and end-of study survey about their work, health, and opinions about COVID-19, and any COVID-19 and influenza vaccines received. Finally, participants who tested positive for COVID-19 during the study or who had COVID-19 symptoms but did not test positive will complete an online survey about the duration of symptoms and impact on their health. By Summer 2024, study staff will inform participants when the weekly surveys will end and when to stop testing. At the end of the study, participants in the vaccinated group will be notified of which study vaccine they received.
At the end of the operation, patients will be randomly divided into 2 groups as Group E (ESP block) and Group Q (QLB). The blocks will be administered under general anesthesia in lateral position by same anesthesiologist. Group E (ESP block) will be applied 20 ml of %0.25 bupivacaine between the erector spina muscle and transverse process at the 8th thoracic level. Group Q (QLB2 block) will be applied 20 ml of %0.25 bupivacaine at lumbar interfacial triangle (LIFT). At the end of the operation, the patients with a Modified aldreate score ≥9 will be sent from the postoperative anesthesia unit. All patients will be equipped with an IV morphine patient-controlled analgesia (PCA) device. The solution will be prepared such that morphine is 0.5 mg / ml. PCA 1mg bolus dose will be delivered with 10 min lock-out time. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 1st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, morphine consumption, initial analgesic requirement, nausea-vomiting score, ramsey sedation scale, length of hospital stay, patient and surgeon satisfaction, and postoperative complications will be recorded.
Participants in cohorts 6-8 will receive SC injection of 2 doses (Part B) of JNJ-75220795 or matching placebo. Participants in cohorts 9-11 will receive SC injection of 4 doses (Part C) of JNJ-75220795 or matching placebo.
Patients will undergo only CRS and IVCT. Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS.
Methods of heterogeneous crystallization and related systems are provided. In some embodiments, a method comprises crystallizing an agent in a suspension comprising a heteronucleant and the dissolved agent. Crystallization may occur on the surface of the heteronucleant with little or no bulk crystallization and/or secondary nucleation. In some embodiments, a crystallizer may be configured to inhibit secondary nucleation and/or bulk crystallization, for example, by reducing the formation of free crystals that may serve as nucleation surfaces while allowing for adequate mass and heat transfer. In some such embodiments, the crystallizer may be designed to flow (e.g., continuously) a suspension comprising a heteronucleant and an agent in a fluidized state. The methods and systems of the present invention may be used in a wide variety of applications, including the crystallization of pharmaceutically active agents.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention claims pharmaceutical composition for oral use prepared by method of humid granulation and comprising N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)- -4-methylpyrazole-3-carboxylic acid amide as active component of the formula:  , its pharmaceutically acceptable salt or solvate in micronized form taken in the amount 0.5-20 wt.%. Composition comprises 0.05-0.5 wt.% of sodium alkyl sulfate, 2.5-10 wt.% of disaggregating agent and pharmaceutical excipients taken among group including binding agents, diluting agents, dyes, spreading agents, perfumes, lubricating agents, antiadhesive agents, the balance up to 100%. Invention claims also method of pharmaceutical composition preparing. Method involves mixing active component, disaggregating agent and sodium alkyl sulfate with diluting agent, binding agent and, if necessary, with dye at the room temperature. Mixture is wetted with purified water and wet mass is dried and screened by grains size. Then lubricating agent and if necessary antiadhesive agent, spreading agent, dye and/or perfume are added to dries screened grains. Invention ensures to provide the complete dissolving composite and improve kinetics of dissolving. Invention can be used in pharmacy for medicinal agents preparing. EFFECT: improved method of preparing. 10 cl, 7 tbl, 7 ex
AIM: Antimuscarinics and the β3-adrenoreceptor agonist, mirabegron, are commonly used for treating patients with overactive bladder (OAB) and α1 -adrenoreceptor antagonists (α1 -blockers) are the main pharmacological agents used for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). As these conditions commonly occur together, the aim of this systematic review was to identify publications that compared the use of an α1 -blocker plus mirabegron with an α1 -blocker plus antimuscarinic in men with LUTS secondary to BPH and OAB. A meta-analysis was subsequently conducted to explore the safety and efficacy of these combinations.
METHODS: Included records had to be from a parallel-group, randomized clinical trial that was ≥8 weeks in duration. Participants were male with LUTS secondary to BPH and OAB. The indirect analyses that were identified compared an α1 -blocker plus OAB agent with an α1 -blocker plus placebo. The PubMed/Medical Literature Analysis and Retrieval System Online, the Excerpta Medica Database, the Cochrane Central Register of Controlled Trials, and the ClinicalTrials.gov registry were searched for relevant records up until March 5, 2020. Safety outcomes included incidences of overall treatment-emergent adverse events (TEAEs) and urinary retention, postvoid residual volume, and maximum urinary flow (Qmax ). Primary efficacy outcomes were micturitions/day, incontinence episodes/day, and urgency episodes/day, and secondary outcomes were Overactive Bladder Symptom Score and International Prostate Symptom Score. A Bayesian network meta-analysis approach was used for the meta-analysis.
RESULTS: Out of a total of 1039 records identified, 24 were eligible for inclusion in the meta-analysis. There were no statistically significant differences between the α1 -blocker plus mirabegron and α1 -blocker plus antimuscarinic groups in terms of the comparisons identified for all the safety and efficacy analyses conducted. Numerically superior results were frequently observed for the α1 -blocker plus mirabegron group compared with the α1 -blocker plus antimuscarinic group for the safety parameters, including TEAEs, urinary retention, and Qmax . For some of the efficacy parameters, most notably micturitions/day, numerically superior results were noted for the α1 -blocker plus antimuscarinic group. Inconsistency in reporting and study variability were noted in the included records, which hindered data interpretation.
CONCLUSION: This systematic review and meta-analysis showed that an α1 -blocker plus mirabegron and an α1 -blocker plus antimuscarinic have similar safety and efficacy profiles in male patients with LUTS secondary to BPH and OAB. Patients may, therefore, benefit from the use of either combination within the clinical setting.
The current practice arm will include: post-operatively, hydrocodone-acetaminophen 5/325mg tabs and ibuprofen 800mg, as needed for pain. Additionally, acetaminophen may be used in conjunction with the above regiment. Ibuprofen and acetaminophen can be taken as needed or alternating every 6 hours, scheduled.
Intervention is whatever Rx the URMC dermatologist thinks is best suited to the subject as part of "real-world" disease management in her clinic. Ages:13-65 yrs of age (inclusive), all genders, races and ethnicities.
<P>PROBLEM TO BE SOLVED: To obtain an antiinflammatory agent comprising an extract from a petal of a rosaceous plant and an antiinflammatory agent composition comprising the extract from the petal of the rosaceous plant and an excipient.  <P>SOLUTION: The anti-inflammatory agent comprises the extract obtained by extracting the petal of the rosaceous plant with a polar solvent as an active ingredient. The antiinflammatory agent is prepared by freeze-drying an aqueous solution of the extract from the petal of the rosaceous plant. In the antiinflammatory agent, the rosaceous plant is a rose. The composition comprises the extract from the petal of the rosaceous plant and further the excipient.  <P>COPYRIGHT: (C)2003,JPO
PURPOSE: To impart, increase, improve or modify perfuming characteristics of perfuming compositions or perfuming products by using specified oxygen-contg. macrocyclic compds. as fragrance ingredients.  
     CONSTITUTION: An effective amt., as fragrance, of a compd. of formula I [wherein Z 1  and Z 2 , taken together, define a group of formula II (in which R 1  and R 2  each represent a 1-6C alkyl or one of them is H and the other is a 1-6C alkyl), or Z 1  is O or OH and Z 2  is OR 3  (in which R 3  is a 1-6C alkyl); the wavy lines define a C-C bond of E or Z configuration when the bonds in positions 4 and 8 are double bonds] such as 12-pentyloxy-4,8- cyclododecadiene-1-one, is added to a perfuming composition or a perfuming product. A ketal of formula V which is one of the compds. of formula I is obtd. by reacting a diol of formula III with a compd. of formula IV in the presence of an acidic substance. The ketal is reacted with a reducing agent to obtain a compd. (hydroxy-ether) of formula I (wherein Z 1  is OH and Z 2  is OR 3 ) and then this compd. is oxidized to obtain a compd. (keto-ether) of formula I (wherein Z 1  is O and Z 2  is OR 3 ). 
     COPYRIGHT: (C)1990,JPO
The therapeutic massage treatments will consist of one 45-minute session weekly, for 3 consecutive weeks. A technique called Fascial Release will be used. Tension related to back pain is believed to be present not only in the back but also in various parts of the body such as the legs, through the connection of fascia, the membrane that surrounds the muscles. The purpose of this treatment is to reduce the tension connected to the lower back.
Systems, methods and computer-readable media for assisting consumers to enroll in a health plan in an online environment. Data comprising residence information, date of birth information and gender information of a consumer is received. Data comprising a type of health insurance product selected by the consumer is received. Data comprising physician information selected by the consumer is received. Result information is retrieved from one or more databases. The result information includes one or more health insurance plans of the type selected by the consumer, and information describing whether physicians associated with the physician information selected by the consumer are included within a network of each of the health insurance plans. The result information is displayed to the consumer. A request from the consumer to enroll in one of the health insurance plans is received.
A system and user interface integrates and processes event associated messages affecting healthcare delivered to a patient and supports creation, initiation and modification of currently operating workflow processes involving processing of event messages. A system for scheduling a set of tasks to be performed by at least one individual to support healthcare delivery employs a method for providing a user interface for processing an event. The event represents a change in circumstances potentially affecting healthcare delivered to a patient. The method involves initiating generation of at least one display image in response to user command. The display image or images support the identification of an event and an associated parameter as well as the designation of a predetermined process associated with the identified event. The display image or images also support user indication of the parameter to be provided to the predetermined process in response to occurrence of the event. The predetermined process comprises a set of tasks to be performed by at least one individual to support healthcare delivery. The display image or images also support designating an executable procedure to be initiated in response to occurrence of the identified event as well as designating a second process to be replaced or supplemented by the predetermined process in response to occurrence of the identified event.
A method and composition for promoting hair growth comprises an oil solution created with predetermined quantities of certain oils such as sesame oil, avocado oil, sweet almond oil, coconut oil, and ricinus oil. A blended final product is created by adding predetermined quantities of certain plants to the oil solution, such as parsley and aloe vera. The final product is heated and applied to a surface for hair growth. After a certain amount of time it is washed off the surface for hair growth. These steps are repeated daily for a full course of treatment, which comprises a few weeks. The course may be repeated about every other month.
The rapidly increasing prevalence of type 1 diabetes (T1D) underscores the role of environmental (i.e. non-genetic) determinants of T1D development. Such factors include industrialized diets as well as the intestinal microbiota with which they interact. One component of industrialized diets that deleteriously impact gut microbiota is dietary emulsifiers, which perturb intestinal microbiota to encroach upon their host promoting chronic low-grade intestinal inflammation and metabolic syndrome. Hence, we investigated whether 2 dietary emulsifiers, carboxymethylcellulose (CMC) and polysorbate-80 (P80), might influence the development of T1D in NOD mice, which spontaneously develop this disorder. We observed that chronic emulsifier exposure accelerated T1D development in NOD mice, which was associated with increased insulin autoantibody levels. Such accelerated T1D development was accompanied by compositional and functional alterations of the intestinal microbiota as well as low-grade intestinal inflammation. Moreover, machine learning found that the severity of emulsifier-induced microbiota disruption had partial power to predict subsequent disease development, suggesting that complex interactions occur between the host, dietary factors, and the intestinal microbiota. Thus, perturbation of host-microbiota homeostasis by dietary emulsifiers may have contributed to the post-mid-20th-century increase in T1D.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes the novel derivatives of pyrone of the general formula (I)   where X, A, A 1 , W, W 1 -W 3 ,R 3 ,R 4 , m and n have values given in p. 1 of the invention claim. Proposed substances can present active component of pharmaceutical composition showing antiviral and antibacterial activity. Invention describes also method of treatment of patients with infection or disease caused by retrovirus by administration of pyrone compounds of the above indicated formula (I) taken in the therapeutically effective amount. EFFECT: valuable antiviral properties, enhanced effectiveness of treatment. 18 cl, 3 tbl, 225 ex
Elderly patients, particularly those with reduced renal or hepatic function, may be at increased risk for developing erythromycin-induced hearing loss. (See ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION).

Elderly patients may be more susceptible to development of torsades de pointes arrhythmias than younger patients. (See WARNINGS.) 

Elderly patients may experience increased effects of oral anticoagulant therapy while undergoing treatment with erythromycin. (See PRECAUTIONS - Drug Interactions).

Erythromycin Tablets (250 mg) contain 8.5 mg (0.4 mEq) of sodium per tablet.

Erythromycin Tablets (500 mg) contain 17 mg (0.7 mEq) of sodium per tablet.

The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as congestive heart failure.
The invention discloses a medicine extract, a composition, preparation methods of the medicine extract and the composition, and a quality control method. The medicine extract is extracted from epigeal srephaia root. The raw materials of the composition comprise ginseng, epigeal srephaia root, astragalus, angelica, and radix ophiopogonis. The composition also can be prepared by ginseng ethanol extract, angelica ethanol extract, epigeal srephaia root total alkaloids, astragalus aqueous extract, and radix ophiopogonis aqueous extract. The quality control method of the composition comprises one or more discrimination methods and measuring methods of content. The invention also discloses applications of the extract and the composition of the medicine in preparation of drugs of abstinence.
It will be consisted of 20 obese women diagnosed as having PCOS. Each will receive placebo laser on acupoints (3 sessions/week, 17 minutes/ session) in addition to low caloric diet for 3 months.
Method and system for controlling oxygen delivery to a cell implant. In one embodiment, the system includes a water electrolyzer, a cell capsule, a gas conduit, a total fluid pressure sensor, and a controller. The water electrolyzer generates gaseous oxygen with a variable output. The cell capsule includes a cell chamber adapted to hold cells. The gas conduit interconnects the water electrolyzer and the cell capsule to deliver gaseous oxygen generated by the water electrolyzer to the cell capsule. The total fluid pressure sensor is positioned at a location that provides a representative reading of the total fluid pressure within the cell chamber. The controller is electrically coupled both to the total fluid pressure sensor and to the water electrolyzer so that the controller may control the variable output of the water electrolyzer based on one or more sensed total pressure readings from the total fluid pressure sensor.
INTRODUCTION: This study aims to investigate the ability of umbilical cord mesenchymal stem cells (UC-MSC) to enhance the regeneration of pulp-dentin complex in immature permanent teeth with irreversible pulpitis.
METHODS: A total of 32 mandibular premolar teeth with immature apices in 5 dogs were used in this in-vivo randomized controlled trial (RCT). Eight healthy teeth without pre-existing pathosis served as the positive control samples and received no treatment, while in another 8 teeth, the pulp was completely extirpated (negative control). Class V cavities were prepared to induce inflammation in the remaining 16 teeth (groups 3 and 4) and the pulp was extirpated 2-4 mm short of the radiographic apex. Of the 16, the 8 teeth in group 4 received 1 mL of cord blood stem cells with a hydrogel scaffold. Blood clots were covered with mineral trioxide aggregates at the cementoenamel junction in the experimental groups, and teeth were filled with RMGI and composite. Three months later, block sections were removed for histologic evaluations for the evaluation of postoperative apical closure, degree of inflammation, and presence of normal pulp tissue. The data were statistically analyzed with the chi-square test (P < .05).
RESULTS: All teeth with complete pulp extirpation demonstrated pulpal necrosis with no postoperative closure of their apices, while apical closure was seen in all the teeth in the remaining groups. There was a statistically significant (P < .001) difference in the presence of inflammation and normal pulp tissue between the experimental groups. The teeth in group 3 showed normal pulp tissue extending to the level of MTA, but there was inflammation within the canal space. In contrast, the teeth in the UC-MSC group demonstrated organized, normal pulp tissue with no inflammation.
CONCLUSION: Based on these results, the regeneration of the pulp-dentin complex is possible with no inflammation when UC-MSCs are used and 2-4 mm of the apical pulp remains intact in immature teeth with irreversible pulpitis.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes new cyclic derivatives of urea of the general formula (I)   where values W, R 4 ,R 4Δ ,R 5 ,R 6 ,R 7 ,R 7Δ  and n are given in p. 1 of the invention claims. Synthesized compounds can be used as inhibitors of retroviral protease activity. Invention describes a pharmaceutical composition based on compounds of the formula (I) and a method of inhibition of retrovirus growth using compounds of the formula (I). EFFECT: enhanced inhibitory activity of compounds. 20 cl, 2 tbl, 22 ex